Phase II Trial of Cystemustine, a New Nitrosourea, as Treatment of High-grade Brain Tumors in Adults.

Autor: Roche, H., Cure, H., Adenis, A., Fargeot, P., Terret, C., Lentz, M.A., Madelmont, J.C., Fumoleau, P., Hanauske, A., Chollet, Ph.
Zdroj: Journal of Neuro-Oncology; Sep2000, Vol. 49 Issue 2, p141-145, 5p
Abstrakt: This study included 39 patients (37 evaluable, of whom 30 patients with recurrent gliomas and 7 patients with gliomas untreated by radiotherapy); they were enrolled into a phase II trial using a new nitrosourea, cystemustine, administrated every 2 weeks at 60 mg/m2 as a 15 min-infusion. Pathology at inclusion was (WHO classification): 14 glioblastomas, 20 grade 3–4 astrocytomas and 3 grade 3 oligodendrogliomas. Four partial responses have been obtained, giving an overall response rate of 10.8%. Four additional patients had a partial response, which for various reasons was not confirmed 4 weeks later; 12 patients had a stable disease for at least 8 weeks, 15 patients had progressive disease. Of the 4 responses, 2 were with a grade 3 oligodendroglioma and 2 glioblastoma. Toxicity (WHO grading) was mainly hematological: leukopenia (16.2% grade 3–4), neutropenia (29.7% grade 3–4), thrombopenia (27% grade 3–4). No other toxicity greater than grade 2 was observed. In conclusion, cystemustine at 60 mg/m2 has moderate clinical activity in relapsing glioma. Our results warrant further investigation of this agent with an increased dose or modified scheme. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: